FDA Grants Approval for Methadone Hydrochloride ANDA212093 by Lannett Co Inc
The FDA has granted approval for the Abbreviated New Drug Application (ANDA) for Methadone Hydrochloride submitted by Lannett Co Inc.
Published: July 24, 2026
Updated: July 24, 2026
Author: Humanexa Intelligence
Therapeutic area: Pain Management / Opioid
Asset: FDA
Regulatory TimelineREG
Fast Track
Breakthrough
Priority Review
PDUFA
Approval
Asset
FDA
Indication
Signal assessment
Signal strength
high
Confidence level
moderate
Signalhigh
Confidencemoderate
Why it matters
The FDA's approval of Lannett's ANDA for Methadone Hydrochloride signifies increased competition in the opioid pain management market. This could impact pricing strategies and market share for existing players in this therapeutic area.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor Lannett's market launch timeline and any subsequent competitive responses from other manufacturers.
Related companies & assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.